|
1
|
Ellenson L: Precursor lesions of
endometrial carcinoma. Springer; New York: 2011, View Article : Google Scholar
|
|
2
|
Trimble CL, Kauderer J, Zaino R,
Silverberg S, Lim PC, Burke JJ II, Alberts D and Curtin J:
Concurrent endometrial carcinoma in women with a biopsy diagnosis
of atypical endometrial hyperplasia: A Gynecologic Oncology Group
study. Cancer. 106:812–819. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bokhman JV: Two pathogenetic types of
endometrial carcinoma. Gynecol Oncol. 15:10–17. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Felix AS, Weissfeld JL, Stone RA, Bowser
R, Chivukula M, Edwards RP and Linkov F: Factors associated with
Type I and Type II endometrial cancer. Cancer Causes Control.
21:1851–1856. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Dong P, Kaneuchi M, Konno Y, Watari H,
Sudo S and Sakuragi N: Emerging therapeutic biomarkers in
endometrial cancer. Biomed Res Int. 2013:1303622013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Suri V and Arora A: Management of
endometrial cancer: A review. Rev Recent Clin Trials. 10:309–316.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Josso N: Professor Alfred Jost: The
builder of modern sex differentiation. Sex Dev. 2:55–63. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Rey R, Lukas-Croisier C, Lasala C and
Bedecarras P: AMH/MIS: What we know already about the gene, the
protein and its regulation. Mol Cell Endocrinol. 211:21–31. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
He WW, Gustafson ML, Hirobe S and Donahoe
PK: Developmental expression of four novel serine/threonine kinase
receptors homologous to the activin/transforming growth factor-beta
type II receptor family. Dev Dyn. 196:133–142. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
MacLaughlin DT, Teixeira J and Donahoe PK:
Perspective: Reproductive tract development-new discoveries and
future directions. Endocrinology. 142:2167–2172. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hudson PL, Dougas I, Donahoe PK, Cate RL,
Epstein J, Pepinsky RB and MacLaughlin DT: An immunoassay to detect
human mullerian inhibiting substance in males and females during
normal development. J Clin Endocrinol Metab. 70:16–22. 1990.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lee MM, Donahoe PK, Hasegawa T, Silverman
B, Crist GB, Best S, Hasegawa Y, Noto RA, Schoenfeld D and
MacLaughlin DT: Mullerian inhibiting substance in humans: Normal
levels from infancy to adulthood. J Clin Endocrinol Metab.
81:571–576. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Fanchin R, Taieb J, Lozano DH, Ducot B,
Frydman R and Bouyer J: High reproducibility of serum
anti-Mullerian hormone measurements suggests a multi-staged
follicular secretion and strengthens its role in the assessment of
ovarian follicular status. Hum Reprod. 20:923–927. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chang HL, Pahlavan N, Halpern EF and
MacLaughlin DT: Serum Müllerian inhibiting substance/anti-Müllerian
hormone levels in patients with adult granulosa cell tumors
directly correlate with aggregate tumor mass as determined by
pathology or radiology. Gynecol Oncol. 114:57–60. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Fuller AF Jr, Krane IM, Budzik GP and
Donahoe PK: Mullerian inhibiting substance reduction of colony
growth of human gynecologic cancers in a stem cell assay. Gynecol
Oncol. 22:135–148. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chin TW, Parry RL and Donahoe PK: Human
müllerian inhibiting substance inhibits tumor growth in vitro and
in vivo. Cancer Res. 51:2101–2106. 1991.PubMed/NCBI
|
|
17
|
Masiakos PT, MacLaughlin DT, Maheswaran S,
Teixeira J, Fuller AF Jr, Shah PC, Kehas DJ, Kenneally MK,
Dombkowski DM, Ha TU, et al: Human ovarian cancer, cell lines, and
primary ascites cells express the human Mullerian inhibiting
substance (MIS) type II receptor, bind, and are responsive to MIS.
Clin Cancer Res. 5:3488–3499. 1999.PubMed/NCBI
|
|
18
|
Stephen AE, Pearsall LA, Christian BP,
Donahoe PK, Vacanti JP and MacLaughlin DT: Highly purified
müllerian inhibiting substance inhibits human ovarian cancer in
vivo. Clin Cancer Res. 8:2640–2646. 2002.PubMed/NCBI
|
|
19
|
Pieretti-Vanmarcke R, Donahoe PK, Szotek
P, Manganaro T, Lorenzen MK, Lorenzen J, Connolly DC, Halpern EF
and MacLaughlin DT: Recombinant human Mullerian inhibiting
substance inhibits long-term growth of MIS type II
receptor-directed transgenic mouse ovarian cancers in vivo. Clin
Cancer Res. 12:1593–1598. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ha TU, Segev DL, Barbie D, Masiakos PT,
Tran TT, Dombkowski D, Glander M, Clarke TR, Lorenzo HK, Donahoe PK
and Maheswaran S: Mullerian inhibiting substance inhibits ovarian
cell growth through an Rb-independent mechanism. J Biol Chem.
275:37101–37109. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang JJ, Roffler SR, Chou HH, Yin FY and
Yin CS: Characterization of mullerian inhibiting substance binding
on cervical carcinoma cells demonstrated by immunocytochemistry.
Tissue Cell. 26:467–476. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Barbie TU, Barbie DA, MacLaughlin DT,
Maheswaran S and Donahoe PK: Mullerian inhibiting substance
inhibits cervical cancer cell growth via a pathway involving p130
and p107. Proc Natl Acad Sci USA. 100:15601–15606. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Segev DL, Ha TU, Tran TT, Kenneally M,
Harkin P, Jung M, MacLaughlin DT, Donahoe PK and Maheswaran S:
Mullerian inhibiting substance inhibits breast cancer cell growth
through an NFkappa B-mediated pathway. J Biol Chem.
275:28371–28379. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Renaud EJ, MacLaughlin DT, Oliva E, Rueda
BR and Donahoe PK: Endometrial cancer is a receptor-mediated target
for Mullerian inhibiting substance. Proc Natl Acad Sci USA.
102:111–116. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chung YJ, Kim HJ, Park SH, Yoon JH, Kim
MR, Nam SW, MacLaughlin DT, Donahoe PK and Kim JH: Transcriptome
analysis reveals that Müllerian inhibiting substance regulates
signaling pathways that contribute to endometrial carcinogenesis.
Int J Oncol. 46:2039–2046. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Akhurst RJ, FitzPatrick DR, Gatherer D,
Lehnert SA and Millan FA: Transforming growth factor betas in
mammalian embryogenesis. Prog Growth Factor Res. 2:153–168. 1990.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Baarends WM, van Helmond MJ, Post M, van
der Schoot PJ, Hoogerbrugge JW, de Winter JP, Uilenbroek JT, Karels
B, Wilming LG, Meijers JH, et al: A novel member of the
transmembrane serine/threonine kinase receptor family is
specifically expressed in the gonads and in mesenchymal cells
adjacent to the müllerian duct. Development. 120:189–197.
1994.PubMed/NCBI
|
|
29
|
di Clemente N, Wilson C, Faure E, Boussin
L, Carmillo P, Tizard R, Picard JY, Vigier B, Josso N and Cate R:
Cloning, expression, and alternative splicing of the receptor for
anti-Mullerian hormone. Mol Endocrinol. 8:1006–1020. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Song JY, Chen KY, Kim SY, Kim MR, Ryu KS,
Cha JH, Kang CS, MacLaughlin DT and Kim JH: The expression of
Müllerian inhibiting substance/anti-Müllerian hormone type II
receptor protein and mRNA in benign, borderline and malignant
ovarian neoplasia. Int J Oncol. 34:1583–1591. 2009.PubMed/NCBI
|
|
31
|
Song JY, Jo HH, Kim MR, Lew YO, Ryu KS,
Cha JH, Kang CS, Donahoe PK, MacLaughlin DT and Kim JH: Expression
of Müllerian inhibiting substance type II receptor and
antiproliferative effects of MIS on human cervical cancer. Int J
Oncol. 40:2013–2021. 2012.PubMed/NCBI
|
|
32
|
Ferenczy A, Bertrand G and Gelfand MM:
Proliferation kinetics of human endometrium during the normal
menstrual cycle. Am J Obstet Gynecol. 133:859–867. 1979. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Bakkum-Gamez JN, Aletti G, Lewis KA,
Keeney GL, Thomas BM, Navarro-Teulon I and Cliby WA: Müllerian
inhibiting substance type II receptor (MISIIR): A novel,
tissue-specific target expressed by gynecologic cancers. Gynecol
Oncol. 108:141–148. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Nicolaije KA, Ezendam NP, Vos MC, Boll D,
Pijnenborg JM, Kruitwagen RF, Lybeert ML and van de Poll-Franse LV:
Follow-up practice in endometrial cancer and the association with
patient and hospital characteristics: A study from the
population-based PROFILES registry. Gynecol Oncol. 129:324–331.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lim MC, Moon EK, Shin A, Jung KW, Won YJ,
Seo SS, Kang S, Kim JW, Kim JY and Park SY: Incidence of cervical,
endometrial, and ovarian cancer in Korea, 1999-2010. J Gynecol
Oncol. 24:298–302. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ko JK, Choi H, Kang WS, Kim MH, Park KH,
Lee CM, Cho YK, Kim BL and Lee HK: Clinical and pathologic study of
abnormal uterine bleeding in premenopausal Women-to evaluate the
prognostic variables of endometrial hyperplasia. Korean J Obstet
Gynecol. 47:139–145. 2004.
|
|
37
|
Kurman RJ, Kaminski PF and Norris HJ: The
behavior of endometrial hyperplasia. A long-term study of
‘untreated’ hyperplasia in 170 patients. Cancer. 56:403–412. 1985.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wang J, Dicken C, Lustbader JW and
Tortoriello DV: Evidence for a Müllerian-inhibiting substance
autocrine/paracrine system in adult human endometrium. Fertil
Steril. 91:1195–1203. 2009. View Article : Google Scholar : PubMed/NCBI
|
